Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Cash from Operations: 2014-2024

Historic Cash from Operations for Cartesian Therapeutics (RNAC) over the last 11 years, with Dec 2024 value amounting to -$23.7 million.

  • Cartesian Therapeutics' Cash from Operations fell 213.94% to -$15.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$63.2 million, marking a year-over-year decrease of 58.24%. This contributed to the annual value of -$23.7 million for FY2024, which is 53.73% up from last year.
  • As of FY2024, Cartesian Therapeutics' Cash from Operations stood at -$23.7 million, which was up 53.73% from -$51.2 million recorded in FY2023.
  • In the past 5 years, Cartesian Therapeutics' Cash from Operations ranged from a high of $34.9 million in FY2020 and a low of -$60.4 million during FY2021.
  • For the 3-year period, Cartesian Therapeutics' Cash from Operations averaged around -$35.5 million, with its median value being -$31.6 million (2022).
  • Per our database at Business Quant, Cartesian Therapeutics' Cash from Operations skyrocketed by 167.82% in 2020 and then plummeted by 273.11% in 2021.
  • Cartesian Therapeutics' Cash from Operations (Yearly) stood at $34.9 million in 2020, then slumped by 273.11% to -$60.4 million in 2021, then soared by 47.62% to -$31.6 million in 2022, then crashed by 61.74% to -$51.2 million in 2023, then skyrocketed by 53.73% to -$23.7 million in 2024.